CGTLive’s Weekly Rewind – September 9, 2022


Review top news and interview highlights from the week ending September 9, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR T/CARVac Therapy Yields Responses in Refractory Testicular Cancer

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.

2. Sequential T-Cell Redirection Therapies Yield Deep, Durable Responses in R/R Multiple Myeloma

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

3. Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal Dementia

The chief medical officer of Passage Bio discussed research needs in FTD.

4. Polycythemia Vera mRNA Therapy Receives FDA Fast Track Designation

SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.

5. Ornithine Transcarbamylase Gene Editing Program Nabs Another FDA Designation

iECURE is planning to submit an IND for GTP-506 in mid-2023.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
© 2024 MJH Life Sciences

All rights reserved.